SCHEMBL4430635

SCHEMBL4430635

OCc1ccc(Cl)cc1Nc1ccnc(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ROCK1 Q13464 2/20 0.39
KDR P35968 2/20 0.39
AURKB Q96GD4 2/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39
IGF1R P08069 1/20 0.39
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
CDK4 P11802 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4441099 0.83 ALDH1A1 (0.44) CYP1A2CYP3A4CYP2C19ROCK1LCK
SCHEMBL5387537 0.80 CYP1A2 (0.56) CYP1A2CYP3A4CYP2C9CYP2C19ROCK1
SCHEMBL4433335 0.75 RECQL (0.41) CYP1A2CYP3A4CYP2C9CYP2C19FGFR1
SCHEMBL4442335 0.75 AURKA (0.37) AURKBDAPK3JAK2PRKD3PRKACA
SCHEMBL30010939 0.75 ROCK1 (0.46) CYP1A2CYP3A4CYP2C9CYP2C19ROCK1
SCHEMBL20162211 0.75 ROCK1 (0.46) CYP1A2CYP3A4CYP2C9CYP2C19ROCK1
SCHEMBL3631100 0.72 MAPK14 (0.45) ABL1LCKFYNBTKSYK
SCHEMBL23887607 0.72 SYK (0.42) ROCK1LCKFGFR1CDK2HTR3E
SCHEMBL4727597 0.71 SYK (0.41) AURKBMAPK8SYKAURKA
SCHEMBL1172235 0.70 EPHB4 (0.40) EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132184-A1 NOVEL PYRIMIDINE DERIVATIVES 698 AstraZeneca AB (SE) 2009-12-16 EP disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO disclosed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 EPHB4, EPHB1, NME2 CYP1A2 2395/4885CYP3A4 1606/4885CYP2C9 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.